A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
Brief description of study
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed/refractory metastatic or locally-advanced solid tumor or lymphoma.
Clinical Study Identifier: s18-01007
ClinicalTrials.gov Identifier: NCT03815682
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
